Integrated Filing — IndAS



General information about company
Scrip Code 506235
NSE Symbol ALEMBICLTD
MSEI Symbol NOTLISTED
ISIN INE426A01027
Name of company Alembic Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2025
Date of end of financial year 31-Mar-2026
Date of board meeting when results were approved 12-Aug-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 01-Aug-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 12-Aug-2025   15:00:00
End date and time of board meeting 12-Aug-2025   15:40:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party?
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.
Whether the company is a high value debt listed entity according to regulation 15 (1A)?
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?
Latest Date on which RPT policy is updated
Indicate Company website link for updated RPT policy of the Company
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 478858000
Other income 34585000
Total income 513443000
2 Expenses
(a) Cost of materials consumed 34546000
(b) Purchases of stock-in-trade 0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 17421000
(d) Employee benefit expense 78266000
(e) Finance costs 4224000
(f) Depreciation, depletion and amortisation expense 26967000
(f) Other Expenses
1 Cost of Construction 100996000 100996000
2 Other Expenses 61853000 61853000
Total other expenses 162849000
Total expenses 324273000
3 Total profit before exceptional items and tax 189170000
4 Exceptional items 0
5 Total profit before tax 189170000
6 Tax expense
7 Current tax 18018000
8 Deferred tax -45000
9 Total tax expenses 17973000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0
11 Net Profit Loss for the period from continuing operations 171197000
12 Profit (loss) from discontinued operations before tax 0
13 Tax expense of discontinued operations 0
14 Net profit (loss) from discontinued operation after tax 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0
16 Total profit (loss) for period 171197000
17 Other comprehensive income net of taxes 42428000
18 Total Comprehensive Income for the period 213625000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 513564000
Face value of equity share capital 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.67
Diluted earnings (loss) per share from continuing operations 0.67
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0
Diluted earnings (loss) per share from discontinued operations 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.67
Diluted earnings (loss) per share from continuing and discontinued operations 0.67
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) 1. The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company. n n2. The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year. n n3. The figures for the quarter ended 31st March, 2025 are the balancing figures between the audited figures in respect of full finanacial year ended 31st March, 2025 and year to date unaudited figures upto third quarter ended 31st December, 2024. n n4. Figures rounded off to the nearest decimal.



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025
Date of end of reporting period 30-Jun-2025
Whether accounts are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Active Pharmaceutical Ingredients Business 129541000 129541000
2 Real Estate Business 349317000 349317000
Total Segment Revenue 478858000
Less: Inter segment revenue 0 0
Revenue from operations 478858000
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Active Pharmaceutical Ingredients Business 27294000 27294000
2 Real Estate Business 149000000 149000000
Total Profit before tax 176294000
i. Finance cost 4224000 4224000
ii. Other Unallocable Expenditure net off Unallocable income -17100000 -17100000
Profit before tax 189170000
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Active Pharmaceutical Ingredients Business 1917044000 1917044000
2 Real Estate Business 4557377000 4557377000
Total Segment Asset 6474421000 6474421000
Un-allocable Assets 3984687000 3984687000
Net Segment Asset 10459108000 10459108000
4 Segment Liabilities
Segment Liabilities
1 Active Pharmaceutical Ingredients Business 364734000 364734000
2 Real Estate Business 994375000 994375000
Total Segment Liabilities 1359109000 1359109000
Un-allocable Liabilities 354461000 354461000
Net Segment Liabilities 1713570000 1713570000
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Amount of items that will not be reclassified to profit and loss 49507000 49507000
Total Amount of items that will not be reclassified to profit and loss 49507000
2 Income tax relating to items that will not be reclassified to profit or loss 7079000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0
5 Total Other comprehensive income 42428000